![Sudhir Sahasrabudhe](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Sudhir Sahasrabudhe
Directeur/Membre du Conseil chez Utah State University Foundation
Postes actifs de Sudhir Sahasrabudhe
Sociétés | Poste | Début | Fin |
---|---|---|---|
Utah State University Foundation | Directeur/Membre du Conseil | - | - |
Massachusetts Institute of Technology | Corporate Officer/Principal | - | - |
Historique de carrière de Sudhir Sahasrabudhe
Anciens postes connus de Sudhir Sahasrabudhe
Sociétés | Poste | Début | Fin |
---|---|---|---|
MYRIAD GENETICS, INC. | Directeur Technique/Scientifique/R&D | - | - |
Aventis Pharmaceuticals, Inc.
![]() Aventis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aventis Pharmaceuticals, Inc. develops, manufactures and markets pharmaceutical products. The company was founded in 1950 and is headquartered in Bridgewater, NJ. | Directeur Technique/Scientifique/R&D | - | - |
Prolexys Pharmaceuticals, Inc.
![]() Prolexys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Prolexys Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering small molecule drugs that act at novel therapeutic targets. The Company's therapeutic focus is on cancer and cardiovascular indications. Prolexys scientists have exploited proprietary proteomics-related techniques to rapidly and accurately identify drug candidates that interact with targets of interest. The result of targeted drug discovery work at Prolexys is a pipeline of product candidates with high value in areas of unmet medical need. Lead programs include: a) Solid tumor oncology program with a small molecule clinical candidate with selective anti-tumor activity, b) The colon cancer program with novel small molecule compounds targeting the beta-catenin signaling cascade and c) HSP20 antagonists, identified as protein interaction inhibitors from targets validated in asthma and vasorelaxation. | Directeur Général | 01/01/2001 | - |
Directeur Technique/Scientifique/R&D | 01/01/2001 | - |
Formation de Sudhir Sahasrabudhe
University of Baroda | Graduate Degree |
Statistiques
Internationale
Etats-Unis | 6 |
Inde | 2 |
Opérationnelle
Chief Tech/Sci/R&D Officer | 3 |
Chief Executive Officer | 1 |
Graduate Degree | 1 |
Sectorielle
Health Technology | 4 |
Consumer Services | 2 |
Finance | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 1 |
---|---|
MYRIAD GENETICS, INC. | Health Technology |
Entreprise privées | 3 |
---|---|
Prolexys Pharmaceuticals, Inc.
![]() Prolexys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Prolexys Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering small molecule drugs that act at novel therapeutic targets. The Company's therapeutic focus is on cancer and cardiovascular indications. Prolexys scientists have exploited proprietary proteomics-related techniques to rapidly and accurately identify drug candidates that interact with targets of interest. The result of targeted drug discovery work at Prolexys is a pipeline of product candidates with high value in areas of unmet medical need. Lead programs include: a) Solid tumor oncology program with a small molecule clinical candidate with selective anti-tumor activity, b) The colon cancer program with novel small molecule compounds targeting the beta-catenin signaling cascade and c) HSP20 antagonists, identified as protein interaction inhibitors from targets validated in asthma and vasorelaxation. | Health Technology |
Utah State University Foundation | |
Aventis Pharmaceuticals, Inc.
![]() Aventis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aventis Pharmaceuticals, Inc. develops, manufactures and markets pharmaceutical products. The company was founded in 1950 and is headquartered in Bridgewater, NJ. | Health Technology |
- Bourse
- Insiders
- Sudhir Sahasrabudhe
- Expérience